Thomas P. Blackburn
Direktor/Vorstandsmitglied bei Umecrine Cognition AB
Profil
Thomas P.
Blackburn is currently the Director at Umecrine Cognition AB since 2017.
Previously, he held positions such as Acting CEO & Vice President-Clinical Development at Helicon Therapeutics, Senior Director-Medical Affairs at Lundbeck Research USA, Director at GSK Plc, and Vice President-Drug Development Operations at Synaptics, Inc. Blackburn received his undergraduate and doctorate degrees from The University of Manchester.
Aktive Positionen von Thomas P. Blackburn
| Unternehmen | Position | Beginn |
|---|---|---|
Umecrine Cognition AB
 Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Direktor/Vorstandsmitglied | 05.09.2017 |
Ehemalige bekannte Positionen von Thomas P. Blackburn
| Unternehmen | Position | Ende |
|---|---|---|
| GSK PLC | Direktor/Vorstandsmitglied | - |
Lundbeck Research USA, Inc.
 Lundbeck Research USA, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Research USA, Inc. develops pharmaceutical products and information to the medical community. The firm engages in the drug discovery aimed at treating central nervous system diseases by designing small molecule therapeutics. The company was founded in 1990 and is headquartered in Paramus, NJ. | Technik-/Wissenschafts-/F&E-Leiter | - |
| SYNAPTICS INCORPORATED | Geschäftsführer | - |
Helicon Therapeutics, Inc.
 Helicon Therapeutics, Inc. BiotechnologyHealth Technology Helicon Therapeutics, Inc. developed drugs and other therapeutic products. It products include HT-0712 and HT-2157 which are used for the treatment of memory impairment. The company was founded in July 1997 and was headquartered in San Diego, CA. | Präsident | - |
Ausbildung von Thomas P. Blackburn
| The University of Manchester | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SYNAPTICS INCORPORATED | Electronic Technology |
| GSK PLC | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Helicon Therapeutics, Inc.
Helicon Therapeutics, Inc. BiotechnologyHealth Technology Helicon Therapeutics, Inc. developed drugs and other therapeutic products. It products include HT-0712 and HT-2157 which are used for the treatment of memory impairment. The company was founded in July 1997 and was headquartered in San Diego, CA. | Health Technology |
Lundbeck Research USA, Inc.
Lundbeck Research USA, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Research USA, Inc. develops pharmaceutical products and information to the medical community. The firm engages in the drug discovery aimed at treating central nervous system diseases by designing small molecule therapeutics. The company was founded in 1990 and is headquartered in Paramus, NJ. | Health Technology |
Umecrine Cognition AB
Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Health Technology |
